title: Why do some lung cancer patients receive no anticancer treatment?
abstract: BACKGROUND
  A significant proportion of lung cancer patients receive no anticancer treatment. This varies from 19% in USA, 33% in Australia, 37% in Scotland, and 50% in Ireland. The aim of this study was to identify the reasons behind this.
  
  
  METHODS
  The Lung Cancer Multidisciplinary Meeting (MDM) in South-West Sydney prospectively collects data on all patients presented. All new lung cancer patients presented between December 1, 2005, and December 31, 2007, were reviewed. Patients were assigned optimal treatment based on evidence-based guidelines. Those patients in whom guidelines recommended no treatment (GNT) were compared with those whom the MDM recommended no treatment (MNT) and with those who actually received no treatment (ANT).
  
  
  RESULTS
  There were 335 patients with a median age of 69 years. A total of 82% had non-small cell lung cancer, 14% had small cell lung cancer, and 4% had no pathologic diagnosis. Eighty-five percent had locally advanced or metastatic disease. GNT was recommended in 4% (n = 13), MNT in 10% (n = 32) but ANT comprised 20% (n = 66). The differences between GNT and MNT were mainly due to patient comorbidities and clinician decision, but the differences between MNT and ANT were due to patient preference and declining performance status. In multivariate analysis, older age, poorer Eastern Cooperative Oncology Group status, non-small cell lung cancer, and non-English language predicted for ANT.
  
  
  CONCLUSIONS
  The proportion of patients with lung cancer receiving no treatment is greater than that predicted by guidelines or recommended by the MDM but lower than that described in population-based studies suggesting that MDMs can improve treatment utilization in lung cancer.
authors.affiliation: Collaboration for Cancer Outcomes, Research and Evaluation, Liverpool Hospital, Liverpool BC, NSW, Australia. shalini.vinod@sswahs.nsw.gov.au
authors.forename: Shalini K
authors.initials: SK
authors.lastname: Vinod
authors.forename: Mark A
authors.initials: MA
authors.lastname: Sidhom
authors.forename: Gabriel S
authors.initials: GS
authors.lastname: Gabriel
authors.forename: Mark T
authors.initials: MT
authors.lastname: Lee
authors.forename: Geoff P
authors.initials: GP
authors.lastname: Delaney
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000473:pathology / Q000628:therapy*; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia; D018287:Carcinoma, Large Cell / Q000150:complications / Q000473:pathology / Q000628:therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000473:pathology / Q000628:therapy*; D015897:Comorbidity; D003657:Decision Making; D005260:Female; D006801:Humans; D007494:Ireland; D008175:Lung Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018307:Neoplasms, Squamous Cell / Q000150:complications / Q000473:pathology / Q000628:therapy*; D057240:Patient Preference; D011446:Prospective Studies; D012606:Scotland; D055752:Small Cell Lung Carcinoma / Q000150:complications / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States